<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941444</url>
  </required_header>
  <id_info>
    <org_study_id>ANAVEX2-73-RS-002</org_study_id>
    <nct_id>NCT03941444</nct_id>
  </id_info>
  <brief_title>ANAVEX2-73 Study in Patients With Rett Syndrome</brief_title>
  <acronym>AVATAR</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients With Rett Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anavex Life Sciences Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anavex Life Sciences Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ANAVEX2-73-RS-002 is a Phase 2, double-blind, randomized, placebo-controlled dose escalation&#xD;
      safety, tolerability and efficacy study in patients 18 years and older with RTT using&#xD;
      endpoints including multiple clinical and exploratory molecular and biochemical measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2 safety, tolerability and efficacy study is designed as a double-blind,&#xD;
      randomized, placebo-controlled study.&#xD;
&#xD;
      This is a 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of&#xD;
      patients with RTT 18 years or older. A voluntary option will be offered for all patients to&#xD;
      continue a 48-week open label extension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>33 participants: 3 PK open-label followed by 30 double-blind, randomized, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>7 weeks</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] of ANAVEX2-73</measure>
    <time_frame>7 weeks</time_frame>
    <description>PK of ANAVEX2-73 and metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC] of ANAVEX2-73</measure>
    <time_frame>7 weeks</time_frame>
    <description>PK of ANAVEX2-73 and metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid panel</measure>
    <time_frame>7 weeks</time_frame>
    <description>Significant laboratory findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RSBQ</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline to End of Treatment (EOT) in the Rett Syndrome Behaviour Questionnaire (RSBQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline to End of Treatment (EOT) in the Clinical Global Impression Improvement Scale (CGI-I) score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anxiety, Depression, and Mood Scale (ADAMS)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Anxiety, Depression, and Mood Scale (ADAMS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Children's Sleep Habits Questionnaire (CSHQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seizure Frequency via seizure diary</measure>
    <time_frame>7 weeks</time_frame>
    <description>Seizure Frequency via seizure diary</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic variant SIGMAR1, COMT</measure>
    <time_frame>7 weeks</time_frame>
    <description>Genetic variant SIGMAR1, COMT</description>
  </other_outcome>
  <other_outcome>
    <measure>Glutamate Plasma Concentration</measure>
    <time_frame>7 weeks</time_frame>
    <description>Glutamate Plasma Concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>GABA Plasma Concentration</measure>
    <time_frame>7 weeks</time_frame>
    <description>GABA Plasma Concentration</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANAVEX2-73 liquid oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo liquid oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANAVEX2-73</intervention_name>
    <description>Liquid oral solution</description>
    <arm_group_label>Active arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Liquid oral solution</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged â‰¥ 18 years, inclusive.&#xD;
&#xD;
          -  Diagnosis of classic RTT, according to 2010 criteria (Neul et al., 2010), and a MECP2&#xD;
             mutation.&#xD;
&#xD;
          -  Current pharmacological treatment regimen, including supplements, has been stable for&#xD;
             at least 4 weeks.&#xD;
&#xD;
          -  If on antiepileptic drugs (AEDs), 1-4 AEDs allowed. Treatment must be stable (drug,&#xD;
             dose, interval of administration) for 30 days prior to enrollment.&#xD;
&#xD;
          -  If the subject is already receiving stable non-pharmacologic educational, behavioral,&#xD;
             and/or dietary interventions, participation in these programs must have been&#xD;
             continuous during the 90 days prior to the screening visit and subjects or their&#xD;
             parent/caregiver/legally authorized representative (LAR) will not electively initiate&#xD;
             new or modify ongoing interventions for the duration of the study. 'Study duration' is&#xD;
             defined as lasting from the screening visit until the treatment is terminated. For&#xD;
             participants in the 16-21 years range, typical school vacations are not considered&#xD;
             modifications of stable programming.&#xD;
&#xD;
          -  Ability to keep accurate seizure diaries or have caregiver who can keep accurate&#xD;
             seizure diaries.&#xD;
&#xD;
          -  Confirmation from the participant that, if of childbearing potential is not pregnant&#xD;
             through urine pregnancy testing. Female patients of childbearing potential and at risk&#xD;
             for pregnancy must agree to abstinence.&#xD;
&#xD;
          -  Prior to the conduct of study-specific procedures, the subject's parent/caregiver/LAR&#xD;
             must provide written informed consent. If applicable, the research team&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have a progressive medical or neurological condition that in the opinion&#xD;
             of the Investigator would interfere with the conduct of the study.&#xD;
&#xD;
          -  Current clinically significant systemic illness that is likely to result in&#xD;
             deterioration of the patient's condition or affect the patient's safety during the&#xD;
             study.&#xD;
&#xD;
          -  History of clinically evident stroke or clinically significant carotid or&#xD;
             vertebrobasilar stenosis or plaque or other history of neurologic (e.g., head trauma&#xD;
             with loss of consciousness) or psychiatric condition that the Investigator deems may&#xD;
             interfere with interpretability of data.&#xD;
&#xD;
          -  Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or&#xD;
             alkaline phosphatase above 3x upper limit of normal (ULN) as determined during&#xD;
             screening.&#xD;
&#xD;
          -  Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within&#xD;
             the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for&#xD;
             asthma are permitted) or chemotherapeutic agents for malignancy within the last 3&#xD;
             years.&#xD;
&#xD;
          -  Other clinically significant abnormality on physical, neurological, laboratory, or&#xD;
             electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise&#xD;
             the study or be detrimental to the participant.&#xD;
&#xD;
          -  Any known hypersensitivity to any of the excipients contained in the study drug or&#xD;
             placebo formulation.&#xD;
&#xD;
          -  Other co-morbid or chronic illness beyond that known to be associated with RTT.&#xD;
&#xD;
          -  Subjects who plan to initiate or change pharmacologic or nonpharmacologic intervention&#xD;
             during the course of the study.&#xD;
&#xD;
          -  Subjects taking another investigational drug currently or within the last 30 days.&#xD;
&#xD;
          -  Any other criteria (such as a clinically significant screening blood test result),&#xD;
             which in the opinion of the Investigator could interfere with the study conduct or&#xD;
             outcome.&#xD;
&#xD;
          -  Subjects on potent CYP3A4 and CYP2C19 inhibitors and inducers.&#xD;
&#xD;
          -  Patients with hepatic and renal impairment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Walter Kaufmann, MD</last_name>
    <phone>844-689-3939</phone>
    <email>rett@anavex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HammondCare</name>
      <address>
        <city>Greenwich</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hohenerg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Hohenerg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Franklin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine Franklin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital (RMH)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Velakoulis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dennis Velakoulis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry O'Brien, MD</last_name>
    </contact>
    <investigator>
      <last_name>Terry O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Keogh Institute for Medical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuckey, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bronwyn Stuckey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College of London</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Parmala, MD</last_name>
    </contact>
    <investigator>
      <last_name>Santosh Parmala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester CGM, St. Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>UK</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharth Banka, MD</last_name>
      <email>Genetics.Research@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Siddharth Banka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rett Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

